Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ · Healthcare
Xeris Biopharma Holdings, Inc. Operating Income 2020–2025
Xeris Biopharma Holdings, Inc. annual/quarterly operating income history and growth rate from 2020 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Xeris Biopharma Holdings, Inc. operating income for the quarter ending March 31, 2026 was 7.9 M, a 356.18% decrease year-over-year.
- Xeris Biopharma Holdings, Inc. operating income for the twelve months ending March 31, 2026 was 16.0 M, a 139.86% decrease year-over-year.
- Xeris Biopharma Holdings, Inc. annual operating income for 2025 was 24.9 M, a 173.99% decrease from 2024.
- Xeris Biopharma Holdings, Inc. annual operating income for 2024 was -33.6 M, a 23.55% decrease from 2023.
- Xeris Biopharma Holdings, Inc. annual operating income for 2023 was -44.0 M, a 46.29% decrease from 2022.
- Xeris Biopharma Holdings, Inc. annual operating income for 2022 was -81.9 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Xeris Biopharma Holdings, Inc. Operating Income — FAQ
Xeris Biopharma Holdings, Inc. (XERS) operating income over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
What is Xeris Biopharma Holdings, Inc.'s operating income?
Xeris Biopharma Holdings, Inc. (XERS) reported operating income of $25M for fiscal 2025.
Where can I see XERS's operating income history?
The chart and table above show Xeris Biopharma Holdings, Inc.'s operating income by year and by quarter, including the growth rate.